Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

NCT00444314 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: Panzem® NCD
DRUG: Sunitinib Malate

Sponsor

CASI pharmaceuticals, Inc.